Bacitracin

Product description:Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy, isolation of which was first reported in 1945.
As a toxic and difficult-to-use antibiotic, bacitracin does not work well orally. However, it is very effective topically, and is a common ingredient of eye and skin antibiotic preparations. Its action is on gram-positive cell walls. It can cause contact dermatitis and cross-reacts with allergic sensitivity to sulfa-drugs.
When given intramuscularly, bacitracin's absorption is rapid and complete, but its nephrotoxicity (kidney damage potential) has limited its use to infants only, and then in very specific circumstances. In 2010 it was approved by the US FDA by this route for the very narrow indication of treatmnent of infants with staphylococcal pneumonia and empyema when due to organisms shown to be susceptible to bacitracin. It can only be used where adequate laboratory facilities are available for checking the drug's concentration in blood. 
CAS No.:1405-87-4
Synonyms: N-[[(4R)-2-[(1S,2S)-1-Amino-2-methylbutyl]-4,5-dihydro-4-thiazolyl]carbonyl]-L-leucyl-D-alpha-glutamyl-L-isoleucyl-L-lysyl-D-ornithyl-L-isoleucyl-D-phenylalanyl-L-histidyl-D-alpha-aspartyl-L-asparagine (10.4)-lactam 
Molecular formula:  C66H103N17O16S  
Molecular weight:  1422.69  
Safety description:  S24/25